JW Pharmaceutical introduced at this time that it’s going to current the preclinical outcomes of the Wnt hair loss therapy “JW0061” on the “Wnt 2022” convention to be held in Japan from November fifteenth.
The Wnt Conference is a discussion board for world-renowned students and researchers within the area of “Wnt signaling” to alternate the newest analysis outcomes.
This yr marks the fortieth anniversary of the invention of the Wnt protein, and researchers from the United States, Europe, Asia, and Oceania and officers from pharmaceutical and bio corporations are anticipated to collect.
At this convention, JW Pharmaceutical will unveil the newly recognized Mode of Action (MoA) of JW0061 and the efficacy analysis outcomes of animal fashions examined with scientific preparations for the primary time.
This is the primary time for a South Korean pharmaceutical/bio firm to current the analysis outcomes of a brand new drug candidate at a world Wnt convention.
JW0061 is a First-in-Class candidate substance that promotes the differentiation and proliferation of hair follicle stem cells and cells concerned in hair progress by activating the Wnt signaling pathway, which is lowered within the strategy of hair loss.
“From a biological point of view, the Wnt signal is a representative signal transduction system that affects numerous diseases related to regeneration, anti-cancer, and immunity,” said Park Chan-hee, Chief Technology Officer (CTO) of JW Group. “At this conference, we will promote JW’s R&D competitiveness accumulated in the Wnt field and hold various discussions with world-class researchers to develop new drug pipelines.”
저작권자 © Korea IT Times 무단전재 및 재배포 금지